Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 9 of 9 entries
Sorted by: Best Match Show Resources per page
[Antidiabetics].

Horumon to rinsho. Clinical endocrinology

Hirata Y.
PMID: 5895308
Horumon To Rinsho. 1965 Nov;13(11):855-60.

No abstract available.

Cite
Hirata Y. [Antidiabetics]. Horumon To Rinsho. 1965;13(11):855-60
Hirata, Y. (1965). [Antidiabetics]. Horumon to rinsho. Clinical endocrinology, 13(11), 855-60.
Hirata, Y. "[Antidiabetics]." Horumon to rinsho. Clinical endocrinology vol. 13,11 (1965): 855-60.
Hirata Y. [Antidiabetics]. Horumon To Rinsho. 1965 Nov;13(11):855-60. Japanese. PMID: 5895308.
Copy Download .nbib Format: NLM
[Attack and pursuit of oral treatment of diabetes in adults].

Semaine therapeutique

Deuil R, Mundler B, Puech H.
PMID: 5600415
Sem Ther. 1967 Feb;43(2):88-90.

No abstract available.

Cite
Deuil R, Mundler B, Puech H. Attaque et poursuite du traitement oral du diabète de l'adulte. [Attack and pursuit of oral treatment of diabetes in adults]. Sem Ther. 1967;43(2):88-90
Deuil, R., Mundler, B., & Puech, H. (1967). Attaque et poursuite du traitement oral du diabète de l'adulte. [Attack and pursuit of oral treatment of diabetes in adults]. Semaine therapeutique, 43(2), 88-90.
Deuil, R, et al. "Attaque et poursuite du traitement oral du diabète de l'adulte." [Attack and pursuit of oral treatment of diabetes in adults]. Semaine therapeutique vol. 43,2 (1967): 88-90.
Deuil R, Mundler B, Puech H. Attaque et poursuite du traitement oral du diabète de l'adulte. [Attack and pursuit of oral treatment of diabetes in adults]. Sem Ther. 1967 Feb;43(2):88-90. French. PMID: 5600415.
Copy Download .nbib Format: NLM
[Methods for preventing accumulation of oral antidiabetics].

Wiener klinische Wochenschrift

LEYPOLD F.
PMID: 13544244
Wien Klin Wochenschr. 1958 Feb 14;70(7):123-4.

No abstract available.

Cite
LEYPOLD F. Methoden zur Verhütung der Kumulierung von peroralen Antidiabetika. [Methods for preventing accumulation of oral antidiabetics]. Wien Klin Wochenschr. 1958;70(7):123-4
LEYPOLD, F. (1958). Methoden zur Verhütung der Kumulierung von peroralen Antidiabetika. [Methods for preventing accumulation of oral antidiabetics]. Wiener klinische Wochenschrift, 70(7), 123-4.
LEYPOLD, F. "Methoden zur Verhütung der Kumulierung von peroralen Antidiabetika." [Methods for preventing accumulation of oral antidiabetics]. Wiener klinische Wochenschrift vol. 70,7 (1958): 123-4.
LEYPOLD F. Methoden zur Verhütung der Kumulierung von peroralen Antidiabetika. [Methods for preventing accumulation of oral antidiabetics]. Wien Klin Wochenschr. 1958 Feb 14;70(7):123-4. German. PMID: 13544244.
Copy Download .nbib Format: NLM
The genetic architecture of type 2 diabetes pharmacotherapy: the emerging genomic evidence.

Current pharmaceutical design

Kavvoura FK, Pappa M, Evangelou E, Ntzani EE.
PMID: 24040874
Curr Pharm Des. 2014;20(22):3610-9. doi: 10.2174/13816128113196660675.

Response to anti-diabetic medications is not always predictable or favourable even in phenotypically similar type-2 diabetes (T2D) cases. This is not only due to patient's compliance and access to care but is also considered to be an effect of...

Cite
Kavvoura FK, Pappa M, Evangelou E, et al. The genetic architecture of type 2 diabetes pharmacotherapy: the emerging genomic evidence. Curr Pharm Des. 2014;20(22):3610-9doi: 10.2174/13816128113196660675.
Kavvoura, F. K., Pappa, M., Evangelou, E., & Ntzani, E. E. (2014). The genetic architecture of type 2 diabetes pharmacotherapy: the emerging genomic evidence. Current pharmaceutical design, 20(22), 3610-9. https://doi.org/10.2174/13816128113196660675
Kavvoura, F K, et al. "The genetic architecture of type 2 diabetes pharmacotherapy: the emerging genomic evidence." Current pharmaceutical design vol. 20,22 (2014): 3610-9. doi: https://doi.org/10.2174/13816128113196660675
Kavvoura FK, Pappa M, Evangelou E, Ntzani EE. The genetic architecture of type 2 diabetes pharmacotherapy: the emerging genomic evidence. Curr Pharm Des. 2014;20(22):3610-9. doi: 10.2174/13816128113196660675. PMID: 24040874.
Copy Download .nbib Format: NLM
[Antidiabetic agents: also new ways to give old agents].

Medizinische Monatsschrift fur Pharmazeuten

Oberpichler-Schwenk H.
PMID: 21189646
Med Monatsschr Pharm. 2010 Aug;33(8):277.

No abstract available.

Cite
Oberpichler-Schwenk H. Antidiabetika: auch bekannte Wege bieten Neues. [Antidiabetic agents: also new ways to give old agents]. Med Monatsschr Pharm. 2010;33(8):277
Oberpichler-Schwenk, H. (2010). Antidiabetika: auch bekannte Wege bieten Neues. [Antidiabetic agents: also new ways to give old agents]. Medizinische Monatsschrift fur Pharmazeuten, 33(8), 277.
Oberpichler-Schwenk, Heike. "Antidiabetika: auch bekannte Wege bieten Neues." [Antidiabetic agents: also new ways to give old agents]. Medizinische Monatsschrift fur Pharmazeuten vol. 33,8 (2010): 277.
Oberpichler-Schwenk H. Antidiabetika: auch bekannte Wege bieten Neues. [Antidiabetic agents: also new ways to give old agents]. Med Monatsschr Pharm. 2010 Aug;33(8):277. German. PMID: 21189646.
Copy Download .nbib Format: NLM
A closer look at heart failure in patients with concurrent diabetes mellitus using glucose lowering drugs.

Expert review of clinical pharmacology

Shah SR, Iqbal SM, Alweis R, Roark S.
PMID: 30488734
Expert Rev Clin Pharmacol. 2019 Jan;12(1):45-52. doi: 10.1080/17512433.2019.1552830. Epub 2018 Dec 03.

INTRODUCTION: Type 2 diabetes (T2D) is an independent risk factor for heart failure (HF). With concomitant T2D and HF, recent data suggests an incremental risk of cardiovascular death and hospitalization for HF, as compared to patients with HF without...

Cite
Shah SR, Iqbal SM, Alweis R, et al. A closer look at heart failure in patients with concurrent diabetes mellitus using glucose lowering drugs. Expert Rev Clin Pharmacol. 2018;12(1):45-52doi: 10.1080/17512433.2019.1552830.
Shah, S. R., Iqbal, S. M., Alweis, R., & Roark, S. (2019). A closer look at heart failure in patients with concurrent diabetes mellitus using glucose lowering drugs. Expert review of clinical pharmacology, 12(1), 45-52. https://doi.org/10.1080/17512433.2019.1552830
Shah, Syed Raza, et al. "A closer look at heart failure in patients with concurrent diabetes mellitus using glucose lowering drugs." Expert review of clinical pharmacology vol. 12,1 (2019): 45-52. doi: https://doi.org/10.1080/17512433.2019.1552830
Shah SR, Iqbal SM, Alweis R, Roark S. A closer look at heart failure in patients with concurrent diabetes mellitus using glucose lowering drugs. Expert Rev Clin Pharmacol. 2019 Jan;12(1):45-52. doi: 10.1080/17512433.2019.1552830. Epub 2018 Dec 03. PMID: 30488734.
Copy Download .nbib Format: NLM
Sodium-glucose cotransporter-2 inhibitors in type 2 diabetes: a magic potion to reduce heart failure?.

Expert review of clinical pharmacology

Pafili K, Papanas N.
PMID: 31232616
Expert Rev Clin Pharmacol. 2019 Aug;12(8):693-695. doi: 10.1080/17512433.2019.1635453. Epub 2019 Jun 30.

No abstract available.

Cite
Pafili K, Papanas N. Sodium-glucose cotransporter-2 inhibitors in type 2 diabetes: a magic potion to reduce heart failure?. Expert Rev Clin Pharmacol. 2019;12(8):693-695doi: 10.1080/17512433.2019.1635453.
Pafili, K., & Papanas, N. (2019). Sodium-glucose cotransporter-2 inhibitors in type 2 diabetes: a magic potion to reduce heart failure?. Expert review of clinical pharmacology, 12(8), 693-695. https://doi.org/10.1080/17512433.2019.1635453
Pafili, K, and Papanas, N. "Sodium-glucose cotransporter-2 inhibitors in type 2 diabetes: a magic potion to reduce heart failure?." Expert review of clinical pharmacology vol. 12,8 (2019): 693-695. doi: https://doi.org/10.1080/17512433.2019.1635453
Pafili K, Papanas N. Sodium-glucose cotransporter-2 inhibitors in type 2 diabetes: a magic potion to reduce heart failure?. Expert Rev Clin Pharmacol. 2019 Aug;12(8):693-695. doi: 10.1080/17512433.2019.1635453. Epub 2019 Jun 30. PMID: 31232616.
Copy Download .nbib Format: NLM
Safety of SGLT2 Inhibitors in Patients with Diabetes Mellitus.

Current drug safety

Singh M, Sharma R, Kumar A.
PMID: 30727912
Curr Drug Saf. 2019;14(2):87-93. doi: 10.2174/1574886314666190206164647.

BACKGROUND: Recently, Food and Drug Administration (FDA) has approved sodium/ glucose co-transporter 2 (SGLT2) inhibitors for the treatment of diabetes mellitus. However, regarding adverse drug reactions (ADRs) of SGLT2 inhibitors in large group of population, very less information is...

Cite
Singh M, Sharma R, Kumar A. Safety of SGLT2 Inhibitors in Patients with Diabetes Mellitus. Curr Drug Saf. 2019;14(2):87-93doi: 10.2174/1574886314666190206164647.
Singh, M., Sharma, R., & Kumar, A. (2019). Safety of SGLT2 Inhibitors in Patients with Diabetes Mellitus. Current drug safety, 14(2), 87-93. https://doi.org/10.2174/1574886314666190206164647
Singh, Mahakpreet, et al. "Safety of SGLT2 Inhibitors in Patients with Diabetes Mellitus." Current drug safety vol. 14,2 (2019): 87-93. doi: https://doi.org/10.2174/1574886314666190206164647
Singh M, Sharma R, Kumar A. Safety of SGLT2 Inhibitors in Patients with Diabetes Mellitus. Curr Drug Saf. 2019;14(2):87-93. doi: 10.2174/1574886314666190206164647. PMID: 30727912.
Copy Download .nbib Format: NLM
Diabetes, Antidiabetic Medications and Cancer Risk in Type 2 Diabetes: Focus on SGLT-2 Inhibitors.

International journal of molecular sciences

Dąbrowski M.
PMID: 33562380
Int J Mol Sci. 2021 Feb 07;22(4). doi: 10.3390/ijms22041680.

In the last decade, cancer became the leading cause of death in the population under 65 in the European Union. Diabetes is also considered as a factor increasing risk of cancer incidence and mortality. Type 2 diabetes is frequently...

Cite
Dąbrowski M. Diabetes, Antidiabetic Medications and Cancer Risk in Type 2 Diabetes: Focus on SGLT-2 Inhibitors. Int J Mol Sci. 2021;22(4)doi: 10.3390/ijms22041680.
Dąbrowski, M. (2021). Diabetes, Antidiabetic Medications and Cancer Risk in Type 2 Diabetes: Focus on SGLT-2 Inhibitors. International journal of molecular sciences, 22(4), . https://doi.org/10.3390/ijms22041680
Dąbrowski, Mariusz. "Diabetes, Antidiabetic Medications and Cancer Risk in Type 2 Diabetes: Focus on SGLT-2 Inhibitors." International journal of molecular sciences vol. 22,4 (2021). doi: https://doi.org/10.3390/ijms22041680
Dąbrowski M. Diabetes, Antidiabetic Medications and Cancer Risk in Type 2 Diabetes: Focus on SGLT-2 Inhibitors. Int J Mol Sci. 2021 Feb 07;22(4). doi: 10.3390/ijms22041680. PMID: 33562380; PMCID: PMC7915237.
Copy Download .nbib Format: NLM
Showing 1 to 9 of 9 entries